Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab - Incidence and predictors

British Journal of Haematology

Volumn 136, Issue 6, 2007, Pages 800-805

  Borthakur, Gautam ^a   O'Brien, Susan ^a   Wierda, William G ^a   Thomas, Deborah A ^a   Cortes, Jorge E ^a   Giles, Francis J ^a   Kantarjian, Hagop M ^a   Lerner, Susan ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Autoimmune haemolytic anaemia; Chronic lymphocytic leukaemia; Immune anaemia

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; HAPTOGLOBIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; RITUXIMAB; STEROID;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COOMBS TEST; FEMALE; HEMOLYSIS; HUMAN; HYPERBILIRUBINEMIA; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; RETICULOCYTOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; GLUCOCORTICOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RED-CELL APLASIA, PURE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIDARABINE;

EID: 33847416685     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06513.x     Document Type: Article

References (39)

1. Barcellini, W., Montesano, R., Clerici, G., Zaninoni, A., Imperiali, F.G., Calori, R., Cortelezzi, A. & Zanella, A. (2002) In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. American Journal of Hematology, 71, 177-183.
2. Berentsen, S., Ulvestad, E., Gjertsen, B.T., Hjorth-Hansen, H., Langholm, R., Knutsen, H., Ghanima, W., Shammas, F.V. & Tjonnfjord, G.E. (2004) Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood, 103, 2925-2928.
3. Castro, J., Jimenez-Alonso, J., Sabio, J.M., Rivera-Civico, F., Martin-Armada, M., Rodriguez, M.A., Jaimez, L., Castillo, M.J. & Sanchez-Roman, J. (2003) Salivary and serum beta2-microglobulin and gamma-glutamyl-transferase in patients with primary Sjogren syndrome and Sjogren syndrome secondary to systemic lupus erythematosus. Clinica Chimica Acta, 334, 225-231.
4. Catovsky, D. & Richards, S. (2004) Incidence of hemolytic anemia after chemotherapy in the CLL4 trial. A possible protective role for fludarabine plus cyclophosphamide. Blood, 104, Abstract # 480.
5. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
6. Cox, D.R. (1972) Regression models and life tables. Journal of the Royal Statistical Society, 34, 187.
7. D'Arena, G., Laurenti, L., Capalbo, S., D'Arco, A.M., De Filippi, R., Marcacci, G., Di Renzo, N., Storti, S., Califano, C., Vigliotti, M.L., Tarnani, M., Ferrara, F. & Pinto, A. (2006) Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. American Journal of Hematology, 81, 598-602.
8. Di Raimondo, F., Giustolisi, R., Cacciola, E., O'Brien, S., Kantarjian, H., Robertson, L.B. & Keating, M.J. (1993) Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leukemia and Lymphoma, 11, 63-68.
9. Diehl, L.F. & Ketchum, L.H. (1998) Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Seminars in Oncology, 25, 80-97.
10. Eberl, G., Renggli, J., Men, Y., Roggero, M.A., Lopez, J.A. & Corradin, G. (1999) Extracellular processing and presentation of a 69-mer synthetic polypeptide to MHC class I-restricted T cells. Molecular Immunology, 36, 103-112.
11. Engelfriet, C.P., Overbeeke, M.A. & dem Borne, A.E. (1992) Autoimmune hemolytic anemia. Seminars in Hematology, 29, 3-12.
12. Ghazal, H. (2002) Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood, 99, 1092-1094.
13. Giles, F.J., Bekele, B.N., O'Brien, S., Cortes, J.E., Verstovsek, S., Balerdi, M., Yared, M., Zhou, X., Kantarjian, H.M., Keating, M.J., Thall, P. & Albitar, M. (2003) A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. British Journal of Haematology, 121, 578-585.
14. Gottenberg, J.E., Busson, M., Cohen-Solal, J., Lavie, F., Abbed, K., Kimberly, R.P., Sibilia, J. & Mariette, X. (2005) Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 64, 1050-1055.
15. Gupta, N., Kavuru, S., Patel, D., Janson, D., Driscoll, N., Ahmed, S. & Rai, K.R. (2002) Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia, 16, 2092-2095.
16. Hamblin, T.J. (2006) Autoimmune complications of chronic lymphocytic leukemia. Seminars in Oncology, 33, 230-239.
17. Iannitto, E., Ammatuna, E., Marino, C., Cirrincione, S., Greco, G. & Mariani, G. (2002) Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody. Blood, 99, 1096-1097.
18. Kaplan, E. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457.
19. Keating, M.J., Kantarjian, H., O'Brien, S., Koller, C., Talpaz, M., Schachner, J., Childs, C.C., Freireich, E.J. & McCredie, K.B. (1991) Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. Journal of Clinical Oncology, 9, 44-49.
20. Keating, M.J., O'Brien, S., Lerner, S., Koller, C., Beran, M., Robertson, L.E., Freireich, E.J., Estey, E. & Kantarjian, H. (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood, 92, 1165-1171.
21. Keating, M.J., O'Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., Koller, C., Wierda, W., Detry, M.A., Lynn, A. & Kantarjian, H. (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4079-4088.
22. Kyasa, M.J., Parrish, R.S., Schichman, S.A. & Zent, C.S. (2003) Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. American Journal of Hematology, 74, 1-8.
23. Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M.J., Jaubert, J., Autrand, C., Divine, M., Dreyfus, B., Maloum, K., Travade, P., Dighiero, G., Binet, J.L. & Chastang, C. (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood, 98, 2319-2325.
24. Mauro, F.R., Foa, R., Cerretti, R., Giannarelli, D., Coluzzi, S., Mandelli, F. & Girelli, G. (2000) Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood, 95, 2786-2792.
25. Molica, S., Levato, D., Cascavilla, N., Levato, L. & Musto, P. (1999) Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. European Journal of Haematology, 62, 117-122.
26. Montillo, M., Tedeschi, A. & Leoni, P. (1994) Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia. Leukemia and Lymphoma, 15, 187-188.
27. Myint, H., Copplestone, J.A., Orchard, J., Craig, V., Curtis, D., Prentice, A.G., Hamon, M.D., Oscier, D.G. & Hamblin, T.J. (1995) Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 91, 341-344.
28. Narat, S., Gandla, J., Hoffbrand, A.V., Hughes, R.G. & Mehta, A.B. (2005) Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica, 90, 1273-1274.
29. Nishida, H., Murase, T., Ueno, H., Park, J.W., Yano, T. & Ikeda, Y. (2006) Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia. Leukemia Research, 30, 1589-1590.
30. Paydas, S. (2004) Fludarabine-induced hemolytic anemia: successful treatment by rituximab. The Hematology Journal, 5, 81-83.
31. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. & Smith, P.G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient II. analysis and examples. British Journal of Cancer, 35, 1-39.
32. Raj, K., Narayanan, S., Augustson, B., Ho, A., Mehta, P., Duncan, N., Tauro, S., Mahendra, P., Craddock, C. & Mufti, G. (2005) Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplantation, 35, 299-301.
33. Robak, T., Blonski, J.Z., Kasznicki, M., Blasinska-Morawiec, M., Krykowski, E., Dmoszynska, A., Mrugala-Spiewak, H., Skotnicki, A.B., Nowak, W., Konopka, L., Ceglarek, B., Maj, S., Dwilewicz-Trojaczek, J., Hellmann, A., Urasinski, I., Zdziarska, B., Kotlarek-Haus, S., Potoczek, S. & Grieb, P. (2000) Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood, 96, 2723-2729.
34. Shanafelt, T.D., Madueme, H.L., Wolf, R.C. & Tefferi, A. (2003) Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clinic Proceedings, 78, 1340-1346.
35. Shvidel, L., Shtalrid, M. & Berrebi, A. (2004) Intractable autoimmune hemolytic anemia in B cell chronic lymphocytic leukemia resolved by rituximab. Leukemia and Lymphoma, 45, 1493-1494.
36. Tertian, G., Cartron, J., Bayle, C., Rudent, A., Lambert, T. & Tchernia, G. (1996) Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Hematology and Cell Therapy, 38, 359-360.
37. Tosti, S., Caruso, R., D'Adamo, F., Picardi, A., Ali, E.M., Girelli, G., Mauro, F.R., Maurillo, L. & Amadori, S. (1992) Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Annals of Hematology, 65, 238-239.
38. Weiss, R.B., Freiman, J., Kweder, S.L., Diehl, L.F. & Byrd, J.C. (1998) Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 16, 1885-1889.
39. Zaja, F., Vianelli, N., Sperotto, A., Patriarca, F., Tani, M., Marin, L., Tiribelli, M., Candoni, A., Baccarani, M. & Fanin, R. (2003) Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leukemia and Lymphoma, 44, 1951-1955.